ADA development with Mim8 isbeing assessed.109 For antibodies targeting tissue factor pathway inhibitors, withconcizumab, for instance, 25% of patients in the explorer4 (recruitingpatients with hemophilia A or B and inhibitors)/explorer5 (recruitingpatients with severe hemophilia A without inhibitors) trials developed ADAsduring the main and extension phases, with no apparent clinical effect, withthe exception of one patient for whom the clinical impact was inconclusive.110. This evidence concerns the gene ADA and hemophilia A.